UNSPSC 51241128: Hypromellose

This classification denotes a synthetic polymer, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3NXW29V3WO. European Medicines Agency schedules Hypromellose in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02622MIG. Hypromellose generally arises in the molecular formula (C9H14O6)N.CH3.H. The term 'hypromellose' is a European Pharmacopoeia designation. SMILES: CC(COCC1C(C(C(C(O1)OC)OCC(C)O)OCC(C)O)OC2C(C(C(C(O2)COC)OC3C(C(C(C(O3)CO)OC)O)O)OC)OC)O.

UNSPSC 51241128 Hypromellose, a Commodity code, covers the supply of this cellulose-derived pharmaceutical excipient and active ingredient to state and local government health facilities, including hospitals, clinics, and institutional pharmacies. State and local buyers source hypromellose primarily through cooperative purchasing agreements and multistate pharmaceutical procurement consortia rather than direct spot purchases. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) and similar state-administered purchasing groups serve as the primary issuing bodies, aggregating demand across participating state agencies, counties, and municipalities to leverage volume for competitive pricing. These entities typically solicit through RFPs that bundle hypromellose with broader generic pharmaceutical and OTC product portfolios, requiring vendors to maintain cGMP compliance, Drug Supply Chain Security Act certification, and relationships with authorized pharmaceutical wholesalers.

MMCAP, administered by the Minnesota Department of Administration's Office of State Procurement and participating states including Oregon, posted an RFP on January 20, 2026 (S1070000015802) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products with a response deadline of March 26, 2026. The procurement requires vendors to supply products through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—and mandates submission of detailed product information by National Drug Code, SKU, UPC, strength, dosage form, packaging, and manufacturing location. Awarded vendors will be provided to wholesalers by May 15, 2026, with contracts effective July 1, 2026 for an initial two-year term. Evaluation weighs price competitiveness at 75 percent, with secondary criteria including fixed pricing structure, administrative compliance, EDI capability, and agreement to a 3 percent administrative fee. Vendors must carry commercial general liability insurance of $5,000,000 per occurrence and professional liability of $2,000,000, and all products must possess FDA approval and expiration dates of at least one year from manufacture with minimum six-month shelf life.